Sign In
Get Clay Free →

Suggestions

    Noriyuki Kitamura

    Novartis - Director, Global Indication Lead - CML, Oncology

    Noriyuki Kitamura is an experienced pharmaceutical executive currently serving as the Executive Business Unit Director for Oncology at Gilead Sciences in Tokyo, Japan.1 He has a strong background in oncology marketing and business management.

    Previously, Kitamura held the position of Director, Global Indication Lead - CML, Global Marketing (Hematology), Oncology Business Unit at Novartis from February 2020 to February 2023.1 In this role, he led strategy and tactics planning for the global launch of a new CML drug, conducted global market research, and managed global medical expert engagements.1

    Kitamura's career history includes:

    • Various roles at Novartis, including Group Manager of Hematology Marketing and New Product Planning Manager (2015-2020)1
    • Brand Manager positions at Eli Lilly and Company, focusing on osteoporosis and neuroscience products (2011-2015)1
    • Marketing and product management roles at BenQ Corporation (2003-2007)1

    He holds an MBA in Marketing from HEC Paris and has completed additional education programs at IMD Business School and the University of London.12

    Highlights

    Pleuroparenchymal fibroelastosis-like lesions in patients with ...

    Related Questions

    What are Noriyuki Kitamura's key achievements at Novartis?
    How did Noriyuki Kitamura's role at Gilead Sciences differ from his role at Novartis?
    What strategies did Noriyuki Kitamura implement for the global launch of new CML drugs?
    What is Noriyuki Kitamura's educational background and how has it influenced his career?
    What are Noriyuki Kitamura's main responsibilities as the Global Indication Lead for CML at Novartis?
    Noriyuki Kitamura
    Add to my network

    Location

    New York City Metropolitan Area